These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development. Grady C; Shah S; Miller F; Danis M; Nicolini M; Ochoa J; Taylor H; Wendler D; Rid A Vaccine; 2020 Sep; 38(41):6381-6387. PubMed ID: 32826103 [TBL] [Abstract][Full Text] [Related]
4. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues. Baay M; Neels P Biologicals; 2020 Sep; 67():69-74. PubMed ID: 32829985 [TBL] [Abstract][Full Text] [Related]
6. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. Eyal N; Lipsitch M; Smith PG J Infect Dis; 2020 May; 221(11):1752-1756. PubMed ID: 32232474 [TBL] [Abstract][Full Text] [Related]
7. Ethics of controlled human infection to address COVID-19. Shah SK; Miller FG; Darton TC; Duenas D; Emerson C; Lynch HF; Jamrozik E; Jecker NS; Kamuya D; Kapulu M; Kimmelman J; MacKay D; Memoli MJ; Murphy SC; Palacios R; Richie TL; Roestenberg M; Saxena A; Saylor K; Selgelid MJ; Vaswani V; Rid A Science; 2020 May; 368(6493):832-834. PubMed ID: 32381590 [No Abstract] [Full Text] [Related]
8. Controlled Human Infection to Speed Up SARS-CoV-2 Vaccine Development. Baay M; Neels P Front Immunol; 2021; 12():658783. PubMed ID: 33777056 [No Abstract] [Full Text] [Related]
9. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies? Schaefer GO; Tam CC; Savulescu J; Voo TC Vaccine; 2020 Jul; 38(33):5085-5088. PubMed ID: 32540271 [TBL] [Abstract][Full Text] [Related]
12. Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project). Korang SK; Juul S; Nielsen EE; Feinberg J; Siddiqui F; Ong G; Klingenberg S; Veroniki AA; Bu F; Thabane L; Thomsen AR; Jakobsen JC; Gluud C Syst Rev; 2020 Nov; 9(1):262. PubMed ID: 33218366 [TBL] [Abstract][Full Text] [Related]
13. Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Mirzaei R; Mohammadzadeh R; Mahdavi F; Badrzadeh F; Kazemi S; Ebrahimi M; Soltani F; Kazemi S; Jeda AS; Darvishmotevalli M; Yousefimashouf R; Keyvani H; Karampoor S Int Immunopharmacol; 2020 Nov; 88():106928. PubMed ID: 32862110 [TBL] [Abstract][Full Text] [Related]
14. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Pollet J; Chen WH; Strych U Adv Drug Deliv Rev; 2021 Mar; 170():71-82. PubMed ID: 33421475 [TBL] [Abstract][Full Text] [Related]